 |
| Kat-cafè in Munich |
This conference intends to gather the leading pharmaceutical and biotech professionals for 3 days of practical discussion on the protection of pharmaceutical drugs based on patent and regulatory exclusivities. Represented companies include, amongst others: Bayer, Haleon, Polpharma, Novo Nordisk, Amgen, Fresenius Kabi, Regeneron, and Sandoz.
According to the organizers, the 2024 edition’s highlights include:
- A review of the latest decisions regarding the SPC waiver and its impact upon your generic and innovator life science exclusivity strategy.
- The intersection between regulatory and IP law with industry-led sessions on: clinical trials, data exclusivity, a Tecfidera case law review and the Pharmaceutical Strategy for Europe.
- The requirements for patentability within the life sciences industry with panel sessions on patent quality, G2/21, enablement and the PTAB.
- The ways in which the UPC is impacting your life science strategy with an industry-led session and judges panel.
An up-to-date agenda can be viewed here.
Once again, this year’s summit will host the pre-event SPC & PTE Forum 2024, allowing a mixed audience of in-house counsel, private practice members and key regulators to discuss the strategies and updates concerning SPCs and PTEs.
IPKat readers are entitled to a 15% discount in the registration fee using VIP code IPKAT_SM at checkout. For further information and to register, click here.
Life Science Strategy Summit on IP & Exclusivity returns to Munich with 15% IPKat readers’ discount
Reviewed by Eleonora Rosati
on
Tuesday, June 04, 2024
Rating:
Reviewed by Eleonora Rosati
on
Tuesday, June 04, 2024
Rating:
Follow the IPKat on LinkedIn 
![[Guest post] CJEU: New licensing rules for the provision of guest TVs in Germany?](https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEiTkKjlDLDY0vCaN4WBm52qPR4i1JN98PwCk2HVRDkrU9L_bproaKW7MPgKXaugWKhoFrd9y6Rq78N0DzGO9SmoO5mjmkWwvrcKe8CRlbMZ9AZhHWlObTtnWdD2OJxOvXPP2KbdT4kQqPVeaF-RTShlmUpuToro-3gzcSIKhi8ohQQOn9j_3utg4Q/s72-c/Picture%201.jpg)
![[Guest post] BASMATI trade mark refused registration in New Zealand](https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjktzglti5Ydx8HpsyMp1A2ffdVYhiSIQ1oHvo1sHQF2kOfxGdRwuWvKiZ6NmlfMMzrtlvFe3j3siY-Etdt5KquPVJleSdVttrD30ERJbgSHho8qinzMi0UQguN0MvzI_55RQ3_5ueYyMCiFfSKstrppd6aSo0tgAphaQ7Ah2FO-ZvzOExt7J2b5w/s72-w320-c-h193/maxresdefault.jpg)
Posts
No comments:
All comments must be moderated by a member of the IPKat team before they appear on the blog. Comments will not be allowed if the contravene the IPKat policy that readers' comments should not be obscene or defamatory; they should not consist of ad hominem attacks on members of the blog team or other comment-posters and they should make a constructive contribution to the discussion of the post on which they purport to comment.
It is also the IPKat policy that comments should not be made completely anonymously, and users should use a consistent name or pseudonym (which should not itself be defamatory or obscene, or that of another real person), either in the "identity" field, or at the beginning of the comment. Current practice is to, however, allow a limited number of comments that contravene this policy, provided that the comment has a high degree of relevance and the comment chain does not become too difficult to follow.
Learn more here: http://ipkitten.blogspot.com/p/want-to-complain.html